EXCEED THE SPACE PROVIDED. Recent human trials report that for patients with established atherosclerotic lesions, vitamin E (E) treatment does not reverse this process, thus concluding that E supplementation does not reduce mortality from coronary heart disease (CHD). Yet, much convincing epidemiological and experimental evidence indicates the potential preventive rather than therapeutic effect of E supplementation on reducing the risk of atherosclerosis and CHD. To date, no controlled studies have been conducted to demonstrate the preventive role of E supplementation started at an early age on atherosclerosis. We hypothesize that 'supplementation with vitamin E from an early age prevents or retards the development of atherosclerosis and the risk of CHD in individuals with either Western dietary habits (high fat/cholesterol) or a reduced intake of fat and cholesterol.' Since long-life E supplementation studies on humans is not practical, we propose testing this hypothesis on a LDL-receptor deficient (LDLR-/-) mouse by feeding mice: a) moderate or b) high fat/cholesterol diet from the age of 5 wks and supplementing both groups' diets with E starting from ages 5 weeks, 6 and 12 mo, to the age of 18 mo. The extent of aortic lesions will be examined by en face microscopic examination, immunohistochemistry, and molecular techniques. The presence and extent of oxidized LDL, macrophages, T cells, and smooth muscle cell populations, as well as endothelial cells expression of adhesion molecules, ICAM-1, VCAM-1, and PCAM-1, will be measured by immunohistochemistry, while aortic expression of mRNA for adhesion molecules as well as inflammatory cytokines and chemokines will be measured by using RT-PCR analysis. In addition, gene chip microarray techniques will be used to determine responsive genes to dietary interventions. The study's results will provide valuable information on the potential preventive role of E supplementation started early in life compared to middle and later ages in reducing the risk of atherosclerosis, the leading cause of morbidity and mortality from CHD in the US. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL069897-03
Application #
6833427
Study Section
Nutrition Study Section (NTN)
Program Officer
Ershow, Abby
Project Start
2003-01-01
Project End
2006-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
3
Fiscal Year
2005
Total Cost
$237,750
Indirect Cost
Name
Tufts University
Department
Type
Schools of Medicine
DUNS #
039318308
City
Boston
State
MA
Country
United States
Zip Code
02111